Pacific Biosciences of California, Inc. (PACB) Profit Margins
Over the twelve months to 2026-06-30, Pacific Biosciences of California, Inc. (PACB) had gross margin 36.4%, operating margin -83.5%, net margin -82.5%, free cash flow margin -77.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PACBPacific Biosciences of California, Inc.Follow PACB — free
—
Price chart with a free account
- Market cap
- 655.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 38.5% | 3.6% | 22.8% | 38.6% | 57.6% | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% | 36.4% | |
| Operating margin | — | — | -275.2% | -103.7% | -31.4% | -78.5% | -96.1% | -128.4% | -110.6% | -132.3% | -161.2% | -239.4% | -166.8% | -308.0% | -346.2% | -83.5% | |
| Net margin | -323.0% | -363.6% | -281.4% | -109.2% | -34.2% | -82.0% | -98.6% | -130.4% | -92.6% | 37.3% | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% | -82.5% | |
| FCF margin | -331.5% | -302.2% | -109.1% | -87.6% | -54.9% | -83.9% | -83.4% | -86.8% | -89.3% | 23.4% | -89.7% | -218.2% | -133.7% | -137.8% | -71.2% | -77.5% |
USD billions · SEC XBRL
Pacific Biosciences of California, Inc. — questions
- What is Pacific Biosciences of California, Inc.'s gross margin?
- 36.4% over the twelve months to 2026-06-30.
- What is Pacific Biosciences of California, Inc.'s operating margin?
- -83.5% over the twelve months to 2026-06-30.
- What is Pacific Biosciences of California, Inc.'s net profit margin?
- -82.5% over the twelve months to 2026-06-30.
Every figure on this page comes from Pacific Biosciences of California, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.